Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RICARDO RESTREPO-JARAMILLO

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1295994952
CMS profile
1054470
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$115,343.27

157 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RICARDO RESTREPO-JARAMILLO

NPI 1295994952 · CMS profile ID 1054470

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295994952?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RICARDO RESTREPO-JARAMILLO, NPI 1295994952, CMS profile ID 1054470. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295994952?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). RICARDO RESTREPO-JARAMILLO, NPI 1295994952, CMS profile ID 1054470. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295994952?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
RICARDO RESTREPO-JARAMILLO, NPI 1295994952, CMS profile ID 1054470, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 157 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1295994952?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

157 matching records · $115,343.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 157 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 157.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
United Therapeutics Corporation $34.1005/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242551374 CMS
Merck Sharp & Dohme LLC $5,760.0005/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1237997644 CMS
Merck Sharp & Dohme LLC $75.0005/16/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238035858 CMS
Actelion Pharmaceuticals US, Inc. $5.5005/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174209510 CMS
Merck Sharp & Dohme LLC $125.0005/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238157353 CMS
United Therapeutics Corporation $20.8905/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242548304 CMS
United Therapeutics Corporation $3,960.0005/06/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1242549070 CMS
Actelion Pharmaceuticals US, Inc. $3,270.0005/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174209714 CMS
Merck Sharp & Dohme LLC $29.3805/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238293309 CMS
Actelion Pharmaceuticals US, Inc. $120.1804/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174209037 CMS
United Therapeutics Corporation $940.7004/30/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242527218 CMS
United Therapeutics Corporation $15.9104/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242527226 CMS
Bayer Healthcare Pharmaceuticals Inc. $2,100.0004/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1225736031 CMS
United Therapeutics Corporation $3,960.0004/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1242547176 CMS
United Therapeutics Corporation $23.8504/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242556258 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.5904/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222732220 CMS
United Therapeutics Corporation $373.2704/23/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242527884 CMS
Actelion Pharmaceuticals US, Inc. $545.0004/22/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174209166 CMS
United Therapeutics Corporation $37.3704/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242547900 CMS
United Therapeutics Corporation $362.2504/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242528552 CMS
United Therapeutics Corporation $114.3004/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242547284 CMS
United Therapeutics Corporation $105.3704/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242556290 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.4103/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222732218 CMS
Bayer Healthcare Pharmaceuticals Inc. $31.0803/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225736023 CMS
Merck Sharp & Dohme LLC $25.7903/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238207386 CMS
United Therapeutics Corporation $607.7903/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242528420 CMS
Actelion Pharmaceuticals US, Inc. $99.9503/12/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1174208992 CMS
United Therapeutics Corporation $24.3403/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242545178 CMS
United Therapeutics Corporation $29.6403/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242545176 CMS
Actelion Pharmaceuticals US, Inc. $3,815.0003/04/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174209347 CMS
Actelion Pharmaceuticals US, Inc. $89.0303/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174209582 CMS
Actelion Pharmaceuticals US, Inc. $139.9902/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174209052 CMS
Actelion Pharmaceuticals US, Inc. $258.7702/26/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174209441 CMS
United Therapeutics Corporation $30.4302/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242545174 CMS
Mallinckrodt Hospital Products Inc. $27.6202/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211993447 CMS
Actelion Pharmaceuticals US, Inc. $186.0302/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174209333 CMS
Actelion Pharmaceuticals US, Inc. $288.2902/24/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174209518 CMS
Actelion Pharmaceuticals US, Inc. $3,815.0002/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1174209513 CMS
Johnson & Johnson Health Care Systems Inc. $28.9702/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1173788458 CMS
Actelion Pharmaceuticals US, Inc. $102.0002/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174209145 CMS
Actelion Pharmaceuticals US, Inc. $2.9002/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174209255 CMS
Actelion Pharmaceuticals US, Inc. $23.3802/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174209275 CMS
United Therapeutics Corporation $33.6802/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242528906 CMS
United Therapeutics Corporation $21.6902/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242542548 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.4602/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223877796 CMS
United Therapeutics Corporation $732.7402/03/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1242526430 CMS
United Therapeutics Corporation $3,400.0001/30/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1242547042 CMS
Actelion Pharmaceuticals US, Inc. $5.5001/29/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1174209031 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $28.2101/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222732216 CMS
United Therapeutics Corporation $121.8101/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242551978 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $96,714.87 103
PY2020 $27,983.79 36
PY2021 $74,814.09 68
PY2022 $67,261.72 80
PY2023 $73,412.91 86
PY2024 $98,994.48 132
PY2025 $115,343.27 157

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $404,877.80 33
PY2024 Principal investigator $556,308.10 57
PY2023 Principal investigator $400,793.84 31
PY2022 Principal investigator $403,895.14 27
PY2021 Principal investigator $85,468.44 51
PY2020 Recipient $1,624.50 1
PY2020 Principal investigator $230,896.75 56
PY2019 Recipient $1,352.37 7
PY2019 Principal investigator $307,809.93 52

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

33 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $270,179.19 12/31/2025 Non-covered Recipient Entity
Tampa General Hospital
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo for the Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension Cpc-PH due to Heart Failure with Preserved Ejection F No dispute reported 06/30/2026 1232938876
Principal investigator 1 United Therapeutics Corporation $600.75 12/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242389915
Principal investigator 1 United Therapeutics Corporation $2,802.00 12/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242389917
Principal investigator 1 United Therapeutics Corporation $11,864.50 12/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION (PHINDER) No dispute reported 06/30/2026 1242389919
Principal investigator 1 Merck Sharp & Dohme LLC $4,157.34 12/11/2025 Non-covered Recipient Entity
University of South Florida
An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension PAH Therapy for the Treatment of PAH No dispute reported 06/30/2026 1232938142
Principal investigator 1 Liquidia Technologies, Inc. $341.55 12/09/2025 Non-covered Recipient Entity
University Of Florida Board Of Trustees
A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients No dispute reported 06/30/2026 1208893974
Principal investigator 1 Liquidia Technologies, Inc. $341.55 12/09/2025 Non-covered Recipient Entity
University Of Florida Board Of Trustees
A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients No dispute reported 06/30/2026 1208893976
Principal investigator 1 Liquidia Technologies, Inc. $2,948.40 12/04/2025 Non-covered Recipient Entity
University Of Florida Board Of Trustees
A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients No dispute reported 06/30/2026 1208893978
Principal investigator 1 Liquidia Technologies, Inc. $221.40 12/04/2025 Non-covered Recipient Entity
University Of Florida Board Of Trustees
A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients No dispute reported 06/30/2026 1208893994
Principal investigator 1 Liquidia Technologies, Inc. $334.80 12/04/2025 Non-covered Recipient Entity
University Of Florida Board Of Trustees
A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients No dispute reported 06/30/2026 1208894006
Principal investigator 1 Liquidia Technologies, Inc. $375.00 12/04/2025 Non-covered Recipient Entity
University Of Florida Board Of Trustees
A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients No dispute reported 06/30/2026 1208894008
Principal investigator 1 Liquidia Technologies, Inc. $2,234.25 12/04/2025 Non-covered Recipient Entity
University Of Florida Board Of Trustees
A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients No dispute reported 06/30/2026 1208894028
Principal investigator 1 United Therapeutics Corporation $133.65 12/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242390127
Principal investigator 1 United Therapeutics Corporation $1,500.00 12/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242390133
Principal investigator 1 Novartis Pharmaceuticals Corporation $30,059.49 12/01/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA HEALTH
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of LTP001 in Healthy Adult Participants (Part A) and to Evaluate the Efficacy and Safety of LTP001 for th No dispute reported 06/30/2026 1190310288
Principal investigator 1 United Therapeutics Corporation $5,837.40 11/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242390137
Principal investigator 1 United Therapeutics Corporation $135.00 10/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242390129
Principal investigator 1 United Therapeutics Corporation $6,159.30 10/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242390139
Principal investigator 1 United Therapeutics Corporation $1,275.00 08/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242390131
Principal investigator 1 United Therapeutics Corporation $4,470.00 08/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242390135
Principal investigator 1 United Therapeutics Corporation $10,713.00 08/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) No dispute reported 06/30/2026 1242390141
Principal investigator 1 United Therapeutics Corporation $5,690.00 06/25/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242389935
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $5,635.00 06/01/2025 Non-covered Recipient Entity
Tampa General Hospital Pulmonology
BAY 632521, RiOciguAt UseRs Registry The ROAR registry No dispute reported 06/30/2026 1225419811
Principal investigator 1 United Therapeutics Corporation $4,773.60 04/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242389933
Principal investigator 1 United Therapeutics Corporation $1,508.00 04/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso No dispute reported 06/30/2026 1242389961
Principal investigator 1 United Therapeutics Corporation $2,958.33 04/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242389931
Principal investigator 1 United Therapeutics Corporation $13,487.85 04/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242389937
Principal investigator 1 United Therapeutics Corporation $520.00 03/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242389923
Principal investigator 1 United Therapeutics Corporation $1,300.00 03/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242389925
Principal investigator 1 United Therapeutics Corporation $1,755.00 02/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242389929
Principal investigator 1 United Therapeutics Corporation $118.35 01/29/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242389921
Principal investigator 1 United Therapeutics Corporation $1,625.00 01/29/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 4, PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY OF A MEAN PULMONARY ARTERY PRESSURE-TARGETED APPROACH WITH EARLY AND RAPID TREPROSTINIL THERAPY TO REVERSE RIGHT VENTRICULAR REMODELING IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: ARTISAN (AFTERLOAD REDUCTION TO IMPROVE RIGHT VENTRICULAR STRUCTURE AND FUNCTION) No dispute reported 06/30/2026 1242389927
Principal investigator 1 United Therapeutics Corporation $8,823.10 01/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso No dispute reported 06/30/2026 1242389963